OPERANCT05772429
Long-Term Follow-Up of a Cohort of Participants Prescribed Epidyolex in France in a Real-life Setting
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 9 versions: 8 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗
- Notable Eligibility criteria expanded, about 3 words
- Trial completed
- Primary and study completion dates changed from estimate of Jul 2026 to Aug 25, 2026
- Secondary endpoints: details revised at 6 of 16 entries
- Notable Primary and study completion dates: Jul 15, 2024 to Jul 2026
- Trial status: Completed to Active, Not Recruiting
- Study sites: 31 to 29
- Minor Trial status: Recruiting to Completed
- Enrollment target: estimated 150 to confirmed 158
- Primary and study completion dates changed from estimate of Mar 1, 2025 to Jul 15, 2024
- Site details revised at 31 of 31 sites
- Minor Study sites: 32 to 31
- Primary and study completion dates: Mar 2025 to Mar 1, 2025
- Minor Site details revised at 9 of 32 sitesv4
Show 2 earlier versionsHide 2 earlier versions
- Minor Study sites: 21 to 32v3
Notable Trial status: Not Yet Recruiting to Recruitingv2 Show 4 more changesShow less
- Primary endpoint revised
- Start date changed from estimate of Mar 2023 to Apr 17, 2023
- Secondary endpoints: details revised at 2 of 16 entries
- Site details revised at 21 of 21 sites
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Retention Rate Percentage After Initiation of Treatment With Epidyolex
Timeframe: Up to 24 months post-dose.
Secondary (16)
Percent Change From Baseline in Seizure Frequency (Average Per 28 Days)
50% Responder Rate
75% Responder Rate
100% Responder (Seizure Freedom) Rate
Number of Seizure-Free Days (Average Per 28 Days)
Show 11 moreShow less
Longest Duration of Seizure-Free Days in the Last 28 Days
Change From Baseline in Behavior Rating Inventory of Executive Function, Preschool Version (BRIEF-P) Score in Participants Aged ≤5 Years
Change From Baseline in Behavior Rating Inventory of Executive Function (BRIEF) Score in Participants Aged 6 to 18 Years
Change From Baseline in Behavior Rating Inventory of Executive Function, Adult Version (BRIEF- A) Score in Participants Aged >18 Years
Modal Dose of Epidyolex Administered to Participants
Maximum Dose of Epidyolex Administered to Participants
Change from Baseline in Average Daily Dosage of Concomitant Anti-Epileptic Drugs (AEDs) and Other Medicines
Use of Rescue Medication Per Month
Physician Global Clinical Impression of Change (PGIC) Score
Caregiver Global Impression of Change (CGIC) Score
Change from Baseline in Health Utility Index Mark II (HUI-2) Score
Arms and interventions
Epidyolex
Participants will receive Epidyolex in accordance with their routine clinical practice as prescribed by their physician.
Drugs: Epidiolex
Sites
29 sites in 1 country